Snakebite is a neglected tropical disease that results in a variety of systemic and local pathologies in 18 envenomed victims and is responsible for around 138,000 deaths every year. Many snake venoms cause 19 severe coagulopathy that makes victims vulnerable to suffering life-threating haemorrhage. The 20 mechanisms of action of coagulopathic snake venom toxins are diverse and can result in both anticoagulant 21 and procoagulant effects. However, because snake venoms consist of a mixture of numerous protein and 22 peptide components, high throughput characterizations of specific target bioactives is challenging. In this 23 study, we applied a combination of analytical and pharmacological methods to identify snake venom toxins 24 from a wide diversity of snake species that perturb coagulation. To do so, we used a high-throughput 25 screening approach consisting of a miniaturised plasma coagulation assay in combination with a venom 26 nanofractionation approach. Twenty snake venoms were first separated using reversed-phase liquid 27 chromatography, and a post-column split allowed a small fraction to be analyzed with mass spectrometry, 28 while the larger fraction was collected and dispensed onto 384-well plates before direct analysis using a 29 plasma coagulation assay. Our results demonstrate that many snake venoms simultaneously contain both 30 procoagulant and anticoagulant bioactives that contribute to coagulopathy. In-depth identification analysis 31 from seven medically-important venoms, via mass spectrometry and nanoLC-MS/MS, revealed that 32 phospholipase A 2 toxins are frequently identified in anticoagulant venom fractions, while serine protease 33 and metalloproteinase toxins are often associated with procoagulant bioactivities. The nanofractionation 34 and proteomics approach applied herein seems likely to be a valuable tool for the rational development of 35 next-generation snakebite treatments by facilitating the rapid identification and fractionation of 36 coagulopathic toxins, thereby enabling specific targeting of these toxins by new therapeutics such as 37 monoclonal antibodies and small molecule inhibitors.
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High throughput screening and identification of coagulopathic snake venom proteins and 2 peptides using nanofractionation and proteomics approaches 
53
Snakebite is a medically important neglected tropical disease, with up to 5.5 million people bitten annually
54
(1). These bites result in as many as 1.8 million envenomings and 138,000 deaths each year, with three to 98% ACN, 2% H 2 O and 0.1% FA. A linear increase of mobile phase B from 0% to 50% in 20 min was 167 followed by a linear increase from 50% to 90% B in 4 min and a 5 min isocratic separation at 90% B. The 168 starting conditions (0% B) were reached linearly in 1 min and the column was then equilibrated for 10 min 169 at 0% B. The column effluent was split post-column in a 1:9 volume ratio. The larger fraction was sent to a The coagulation cascade interfering properties of snake venoms were analysed using a previously 186 described plasma coagulation assay (19) . Briefly, 20 µL of 20 mM calcium chloride solution (room 187 temperature) was dispensed onto a 384-well plate containing LC fractionated snake venom using a Thermo
188
Scientific multidrop 384 reagent dispenser. Next, 20 µL of bovine plasma (room temperature) was dispensed 189 into each well. Finally, the plate was placed into the plate reader and the absorbance was measured 190 kinetically at 595 nM for 80 cycles (± 90 min) at 25°C.
191
The resulting data was normalized and analysed in three different ways to differentiate between 192 anticoagulant, fast procoagulant and slow procoagulant detected bioactive components First, the last 193 measurement cycle was plotted as a single point measurement to display the anticoagulant compounds.
194
Second, the average slope of cycles 1-5 were plotted to show the fast procoagulant components. Last, the 195 average slope of cycles 1-15 were plotted to show the remainder of the procoagulant components ("slow 196 procoagulants"). The rationale for plotting the procoagulant activity in two different ways is that the fast 197 procoagulant compounds clot the plasma in the wells in a distinct manner, resulting in a rapid rise in 198 absorbance followed by a plateau, and where this plateau typically occurs at a lower overall absorbance 199 than that observed with the "slow procoagulant" components. Thus, wells containing the slower 200 procoagulant components reach an absorbance that surpasses those of the wells containing the fast 201 procoagulants, but over a prolonged period of time.
202 2.5. Correlating coagulation data with mass spectrometry data 203
The elution times and peak widths at half maximum of the peaks observed in the bioassay chromatograms 204 were determined. For the corresponding time interval, the average mass spectrum was extracted from the 205 parallel recorded MS chromatogram (total-ion current (TIC)). For all m/z's with a significant signal in this 206 mass spectrum, extracted-ion currents (XICs) were plotted. Based on matching peak shape and retention 207 time, m/z's were assigned to the appropriate bioactive peaks observed in the bioassay chromatogram 208 based. The charge states of the particular one deconvolutes spectra were assigned by the software based 209 on the observed isotope distribution. Finally, deconvolution of the full mass spectra recorded for the 210 assigned peaks provided the accurate monoisotopic masses.
211
The difference in flow rate of the flow ratio directed to the bioassay and the flow ratio directed to the mass 212 spectrometer after the post-column split caused a constant time delay between the nanofractionated plates 213 and the obtained MS data. To determine the duration of this delay, the thrombin inhibitor argatroban was 214 nanofractionated, resulting in a negative peak in the plasma coagulation assay, which could be correlated 215 to its corresponding known extracted ion current (shown in SI Fig 1) . The difference in elution time between 216 the two peaks is the delay between the MS and the nanofractionation collector and was found to be 78 sec.
217
Using the determined delay, the m/z-values measured in the MS could be correlated with the bioactive 218 peaks observed in the bioassay chromatograms. 219 2.6. Identification of coagulopathic toxins via tryptic digestion
220
After for a specific sample the wells containing bioactive compounds were pinpointed, the same sample was 221 fractionated again, and the content of the active wells was subjected to tryptic digestion in order to identify 222 coagulopathic toxins using a proteomics approach. For that, the plate was first freeze-dried,and then 40 µL 223 of water was added to each selected well, reconstituting the contents for 30 min at room temperature. Next, 224 10 µL from each rwell was transferred to an Eppendorf tube containing 15 µL of digestion buffer (25 mM 225 ammonium bicarbonate, pH 8.2). Subsequently, 1.5 µl of reducing agent (0.5% β-mercaptoethanol) was 226 added to each tube followed by a 10-min incubation at 95 °C. Then, the samples were cooled to room 227 temperature and centrifuged at 150 RCF for 10 s in a Himac CT 15RE centrifuge. Next, 3 µL of alkylating 228 agent (55 mM iodoacetamide) was added and the mixture was incubated in the dark at room temperature 229 for 30 min. Subsequently, 3 µL of 0.1 μg/μL trypsin was added followed by incubation at 37 °C for 3 h, after 230 which an additional 3 µL of trypsin solution was added to the tube and the samples were incubated overnight.
231
Next, 1 μL of 5% FA was added to quench the digestion, followed by brief centrifugation to remove any 232 particulate matter. Finally, the samples were centrifuged for 10 s at 150 RCF and the supernatants were 233 transferred to autosampler vials with glass inserts and analyzed using nanoLC-MS/MS.
234
NanoLC separation of the tryptic digests were performed using an UltiMate 3000 RSLCnano system 235 (Thermo Fisher Scientific, Ermelo, The Netherlands). The autosampler was run in full-loop injection mode.
236
The autosampler was set to a 1 µL injection volume and after injection the samples were separated on an 237 analytical capillary column (150 mm x 75 µm) packed in-house with Aqua C 18 particles (3 µm particle size, 238 200 Å pores; Phenomenex, Utrecht, The Netherlands). The mobile phase was comprised of eluent A (98% 239 water, 2% ACN, 0.1% FA) and eluent B (98% ACN, 2% water, 0.1% FA). The applied gradient was: 2 min 240 isocratic separation at 5% B, linear increase to 80% B in 15 min, 3 min isocratic separation at 80% B, down 241 to 5% B in 0.5 min and equilibration for 9 min. The column was kept at 30 °C in the column oven. Absorbance
242
detection was performed at 254 nm followed by mass detection using a Bruker MaxisII qTOF mass 243 spectrometer (Bruker, Bremen, Germany) equipped with a nanoESI source operating in positive-ion mode.
244
The ESI source parameters were: source temperature, 200 °C; capillary voltage, 4.5 kV; gas flow, 10 L/min.
245
Spectral data were stored at a rate of 1 average spectrum/s in the range of 50 to 3000 m/z. MS/MS spectra 246 were obtained using collision induced dissociation (CID) in data-dependent mode using 35-eV collision 247 energy. Bruker Compass software was used for instrument control and data analysis.
248
Using the data obtained for the tryptic digests of the samples, protein identification was carried out using 249 MASCOT (Matrix Science, London, United Kingdom) searches against Swiss-Prot, NCBInr and species-250 specific databases. The latter were generated from previously published transcriptomic data for those 251 species that were available (24-27) and were used for the identification of venom toxins for which activity Comparisons of the molecular weights of the various procoagulant and anticoagulant venom toxins detected 266 from the seven venoms were performed using the R package Artool (28). The data comprised of the 267 molecular weights of toxin identities found through tryptic digestion and Mascot database searching 268 described above. The full data set of toxin molecular weights can be found in Table 2 . As the compiled data 269 was found to be non-Gaussian in distribution, a non-parametric factorial analysis was performed, which was 270 undertaken using the function art() in Artool (28). The objective of this study was to characterise the coagulopathic activity of various snake venoms and 275 identify their coagulopathic toxins. Our approach consisted of an initial screening strategy, whereby the 276 bioactivity of 20 snake venoms sourced from different taxonomic families and geographic origins were Based on the initial screening, the pro-and anti-coagulant activities of the 20 snake venoms were 293 compared semi-quantitatively based on the observed activity (Table 1) . For a detailed view of the 294 resulting assay data for each of these venoms we direct the reader to SI 
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Calloselasma rhodostoma) or because they represent different snake families (e.g. the elapid species
311
Oxyuranus scutellatus and the colubrid species Dispholidus typus). The results of these optimized 312 experiments demonstrated that all seven of the snake venoms exhibited substantial procoagulant 313 venom activity (Figure 1 ), broadly consistent with our initial venom screen (Table 1) , and recent analyses 314 undertaken using crude venom (7, 22, (29) (30) (31) (32) (33) (34) (35) . The notable exception to this was that of O. scutellatus, 315 which did not exhibit procoagulant activity in our initial screen (Table 1) and their corresponding masses for all bioactives can be found in table 2. This method proved to be 331 successful for masses up to 15 kDa, however larger toxins showed to be much more difficult to correlate.
332
This was most likely caused by a lack of sensitivity of the LC-MS caused by poor ionization or insufficient 333 amounts of the relevant proteins. 
338
The digested content of each well was analysed by nanoLC-MS/MS and the data was subjected to a 339 Mascot database search using the Uniprot database and species-specific databases compiled from 340 transcriptomic data. We noted that the search results provided by the Uniprot database provided a large 341 number of Mascot identities at the timeframes of the pro-and anti-coagulant activities. This is likely the 342 result of the bioactive compound not having an exact match in the database due to low toxin 343 representation, but having high sequence similarity to a number of venom toxins found in related snake 344 species. The toxin identities mentioned in the text below were selected based on the sequence 345 coverage, protein score and known functional activity, and the full results are detailed in the SI Uniprot 346 database table in the Supplementary Information. Thereafter, we compared the deconvoluted 347 monoisotopic masses of the XICs correlated with the bioactive peaks (described above) with the masses 348 of the compounds identified via Mascot to assign protein identities found on Uniprot to coagulopathic 349 venom toxins (Table 2) . This proved to be again successful for smaller toxin components (<15 kDa), 350 but for larger toxins (e.g. >20kDa) none of the XICs could be correlated to Mascot identities (Table 2).  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366 415 
425
Toxin identifications are derived from those described in Table 2 
433
Despite these limitations, summarizing the toxin identities from the Mascot hits and XICs of the various anti-434 and pro-coagulant venom fractions revealed noticeable differences in the masses of the toxins associated 435 with these two bioactivities (Fig 3. Panel C) . In total we detected 59 toxins in the fractions where On the basis of the m/z-values detected for the anticoagulant-active peaks for Bothrops asper, six molecular 448 masses were assigned ( Figure 1 ; Table 1 ). Four of these were found to be proteins of the PLA 2 toxin family.
449
A number of snake venom PLA 2 s have previously been described to exert anticoagulant effects via binding 450 to factor Xa and inhibiting prothrombinase activity (36). One of the four PLA 2 s detected in our study has 451 previously been described to be anticoagulant, namely "Basic phospholipase A2 456 homolog M1-3-3", which is predicted to exert myotoxic activity based on its similarity to PLA 2 s from other 457 snake species (37). The second corresponds to "Basic phospholipase A2 homolog 4a" and exhibits a mass 458~16 Da higher than the PLA 2 toxin, and this slight difference may be caused by an oxidation of methionine.
459
This toxin has only previously been described as myotoxic (38). The third PLA 2 corresponds to "Basic 460 phospholipase A2 myotoxin III" which is also only known to exhibit myotoxic activity (38) (39) (40) (41) (42) (43) (Table 2 ). The Mascot hits found at the timeframe where the procoagulant activity was observed suggest 487 that some of these proteins may be SVSPs that are known to exhibit procoagulant ("Thrombin-like enzyme 488 bothrombin"; sequence coverage (SC) of 22%), platelet aggregating ("Platelet-aggregating proteinase PA-489 BJ"; SC, 49%) or fibrinogenolytic ("Thrombin-like enzyme KN-BJ 2"; SC, 40%) activities. In addition, we 490 detected matches to C-type lectins with known platelet aggregating activities ("Snaclec botrocetin subunit 491 alpha"; SC, 20%) (46), and SVMPs previously described to promote haemorrhage and haemagglutination
492
("Zinc metalloproteinase-disintegrin-like jararhagin" and "Zinc metalloproteinase/disintegrin"; SC, 46% and 493 28%, respectively) (40, (46) (47) (48) (49) .
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this slight difference may be caused by a methylation. , whereas the other protein was much smaller in size We identified three anticoagulant bioactivity peaks in the venom of Echis ocellatus that could be linked to 530 XICs (Figure 2E ), and two of these were matched to Mascot hits. 
532
and matched the PLA 2 toxins "Phospholipase A2 homolog" and "Acidic phospholipase A2 5". Despite these 533 identifications, and prior reports of PLA 2 s generally exerting anticoagulant activities (16), neither of these E.
534
ocellatus PLA 2 s have previously been described as anticoagulants (33, 56, 57) . Despite the venom from 535 these species being potently procoagulant (7, 58), we only identified one XIC that could be correlated to a 536 procoagulant bioactivity peak. This protein had a m/z-value of 1445.8645 35+ and a corresponding mass of 537 52015.873 Da, but could not be matched to a Mascot hit. Nonetheless, the mass recovered suggests that 538 this could be a SVMP, particularly since this venom is known to be dominated by this toxin class (33), and 539 has previously been demonstrated to contain P-III SVMPs of ~52 kDa in size (13), and potent procoagaulant 540 SVMPs, such as the ~55 kDa prothrombin activator ecarin (59). Supporting this tentative toxin assignment,
541
Mascot hits at the timeframe of the procoagulant activity identified known procoagulant SVMP toxins ("Zinc 542 metalloproteinase-disintegrin-like EoVMP2" and "Zinc metalloproteinase-disintegrin-like EoMP06" SC, 48% 543 and 23% sequence coverage, respectively) (60, 61), along with two, much small molecular weight, C-type 544 lectins ("Snaclec 1" and "Snaclec CTL-Eoc124" SC, 53% and 31%). "Zinc metalloproteinase-disintegrin-545 like EoVMP2" is a known prothrombin activator and "Zinc metalloproteinase-disintegrin-like EoMP06" is 546 suspected to activate prothrombin based on its sequence similarity with a prothrombin-activating SVMP of 547 
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these two venom toxins are closely eluting ( Figure 2F) and thus it is possible that only one of these 555 components is responsible for the anticoagulant activity. Based on their molecular weight it is tempting to 556 speculate that this activity likely comes from the ~13 kDa compound, particularly since this mass correlates 557 well with a number of anticoagulants detected from the other venoms under study here (e.g. PLA 2 toxins, 558 13-14 kDa in size). However, given that D. typus is the only colubrid venom investigated in this study, and 559 that colubrid PLA 2 s are distinct from those of vipers (24), this hypothesis requires testing in future work.
560
Nonetheless, these findings are interesting because there are no prior reports of D. typus venom exhibiting 561 anticoagulant activity, likely because this activity is masked by the net procoagulant activity of this venom 562 (7). The procoagulant peak could be correlated to a mass of ~23 kDa (Table 2) . This toxin most likely 563 belongs to the SVMPs family, which are the most dominant toxin type in D. typus venom (24), and have 564 previously been described to be responsible for the potent procoagulant activity of this species (63). 
591
Summarising across the species studied here, we found that many of the anticoagulants detected are likely 592 PLA 2 toxins, as indicated by matching masses for some, and the molecular weights determined by MS for 593 others (i.e. ~13-14 kDa). Contrastingly, only a few of the procoagulant activity peaks observed in the plasma 618 in recovering components above 20 kDa between the LC-MS-bioassay correlation approach and the 619 nanoLC-MS approach. This was most likely caused due to the lack of sensitivity of the LC-MS caused by 620 poor ionization or insufficient amounts of the proteins, as mentioned before. The nanoLC-MS-Mascot 621 approach was far more sensitive due to the much better ionization of peptides compared to intact proteins.
622
Isolation and further elucidation of the toxins correlated to the bioactivity peaks is necessary for the 623 confirmation of their activity. Finally, it is possible that there could be co-eluting bioactive components that 624 were not detected by MS.
626
It has to be mentioned that for most of the seven snakes profiled many more Mascot identities were found 627 at the timeframes of the pro-and anticoagulant activities but that mostly only the ones for which a high 628 sequence coverage and/or an accurate mass was established, were mentioned in the text. The venom toxin 629 identities reported are in some cases from different species than analyzed, which means that the possible 630 bioactive compound is not an exact match, but has high sequence similarity to a venom toxin from another 631 snake species of which the transcriptomic data was available in the Mascot database. 
636
Despite these limitations, the at-line nanofractionation approach in combination with the plasma coagulation 637 assay proved to be a fast and powerful approach for the identification of a number of venom toxins that 638 affect the coagulation cascade. Fig 4. , provides a summary of the toxins that were detected as being 639 procoagulant and anticoagulant from each of the seven snake venoms studied. For the procoagulant 640 activities, SVMPs, SVSPs and C-type lectins were found in five out of the seven species analysed in depth,
641
while LAAOs were found in three of the seven (Fig 4) . These identifications form the basis for future 642 confirmatory studies characterizing the procoagulant activities of the toxins identified here, and for defining 643 those venom components that to not perturb coagulation and were detected here as the result of co-elution.
644
For the anticoagulant activities it became evident that PLA 2 s play an important role for all species included 645 in this study, as at least one PLA 2 was detected in each of the seven venoms. In six of the seven venoms 646 analysed we also detected C-type lectins in bioactive regions, although only one of these was associated 647 with anticoagulant activity (in Oxyuranus scutellatus). This is perhaps surprising given that C-type lectins 648 are predominately associated with anticoagulant activities (17, (74) (75) (76) (77) (78) , however, these toxins may perhaps 649 work in a synergistic manner with other toxins, or may not have been associated with anticoagulant activity 650 here, due to many eluting in the procoagulant timeframe of the bioassay, resulting in anticoagulant activities 651 being masked by procoagulant toxins. While the reverse may also happen (e.g. weakly procoagulant toxins 652 being masked via co-eluting in the anticoagulant areas), it is worth noting that one of the strengths of our 653 approach is the deconvolution of coagulopathic toxin activities from the complex venom mixture, and 654 specifically the identification of anticoagulant venom activity from these 'net' procoagulant venoms. Prior 655 studies using crude venom have demonstrated that the majority of the venoms tested here are procoagulant 656 and potently clot plasma (7, 29, 31, 32, 54, (79) (80) (81) (82) . Despite these observations, our nanofractionation 657 approach clearly reveals that many of these venoms also contain anticoagulant bioactives (e.g. 10 of 20 658 initial venoms, Table 1 ; 7 of 7 venoms analysed in depth; Figures 1 and 2) , which are completely masked 659 when using crude venom in such screening assays. observed bioactivity with high confidence due to correlation with MS data or abundance of the toxin and its 704 known activity. This panel is constructed with the data found in Table 2 . 705 706
Conclusion

707
The results of this study describe the validity of using a medium throughput approach for the identification 708 of venom toxins associated with specific pathogenically-relevant bioactivities. In this case, we applied the 709 screening approach to the topic of coagulopathy, as this is well known to be one of the most frequent, 
